Hepatitis C virus and liver transplantation

Kalyan Ram Bhamidimarri, Sanjaya Satapathy, Paul Martin

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) is a major cause of death from infectious disease and is still the leading indication for liver transplantation in the United States and other Western countries. Alloral, direct-acting antiviral (DAA) therapies have revolutionized the field, with HCV cure rates of more than 90% among treated patients. The safety and tolerability of these DAA agents have expanded the feasibility of HCV treatment even in the challenging pre- and post-liver transplant settings. However, the unique properties of DAA agents and the host profiles in these settings can limit the generalizability of HCV regimens, and prolongation of treatment duration or addition of ribavirin may be required in certain scenarios to optimize treatment outcomes. HCV therapy in the liver transplant setting is not one-size-fits-all; thus, this review summarizes the published data and emphasizes the applicability of currently available DAA therapies in patients with decompensated cirrhosis and in liver transplant recipients.

Original languageEnglish (US)
Pages (from-to)214-220
Number of pages7
JournalGastroenterology and Hepatology
Volume13
Issue number4
StatePublished - Apr 1 2017

Fingerprint

Hepacivirus
Liver Transplantation
Antiviral Agents
Liver
Transplants
Therapeutics
Ribavirin
Liver Cirrhosis
Communicable Diseases
Cause of Death
Safety

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Bhamidimarri, K. R., Satapathy, S., & Martin, P. (2017). Hepatitis C virus and liver transplantation. Gastroenterology and Hepatology, 13(4), 214-220.

Hepatitis C virus and liver transplantation. / Bhamidimarri, Kalyan Ram; Satapathy, Sanjaya; Martin, Paul.

In: Gastroenterology and Hepatology, Vol. 13, No. 4, 01.04.2017, p. 214-220.

Research output: Contribution to journalArticle

Bhamidimarri, KR, Satapathy, S & Martin, P 2017, 'Hepatitis C virus and liver transplantation', Gastroenterology and Hepatology, vol. 13, no. 4, pp. 214-220.
Bhamidimarri, Kalyan Ram ; Satapathy, Sanjaya ; Martin, Paul. / Hepatitis C virus and liver transplantation. In: Gastroenterology and Hepatology. 2017 ; Vol. 13, No. 4. pp. 214-220.
@article{2f397198d74b4f0fbe5a308a47e15bcc,
title = "Hepatitis C virus and liver transplantation",
abstract = "Hepatitis C virus (HCV) is a major cause of death from infectious disease and is still the leading indication for liver transplantation in the United States and other Western countries. Alloral, direct-acting antiviral (DAA) therapies have revolutionized the field, with HCV cure rates of more than 90{\%} among treated patients. The safety and tolerability of these DAA agents have expanded the feasibility of HCV treatment even in the challenging pre- and post-liver transplant settings. However, the unique properties of DAA agents and the host profiles in these settings can limit the generalizability of HCV regimens, and prolongation of treatment duration or addition of ribavirin may be required in certain scenarios to optimize treatment outcomes. HCV therapy in the liver transplant setting is not one-size-fits-all; thus, this review summarizes the published data and emphasizes the applicability of currently available DAA therapies in patients with decompensated cirrhosis and in liver transplant recipients.",
author = "Bhamidimarri, {Kalyan Ram} and Sanjaya Satapathy and Paul Martin",
year = "2017",
month = "4",
day = "1",
language = "English (US)",
volume = "13",
pages = "214--220",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "4",

}

TY - JOUR

T1 - Hepatitis C virus and liver transplantation

AU - Bhamidimarri, Kalyan Ram

AU - Satapathy, Sanjaya

AU - Martin, Paul

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Hepatitis C virus (HCV) is a major cause of death from infectious disease and is still the leading indication for liver transplantation in the United States and other Western countries. Alloral, direct-acting antiviral (DAA) therapies have revolutionized the field, with HCV cure rates of more than 90% among treated patients. The safety and tolerability of these DAA agents have expanded the feasibility of HCV treatment even in the challenging pre- and post-liver transplant settings. However, the unique properties of DAA agents and the host profiles in these settings can limit the generalizability of HCV regimens, and prolongation of treatment duration or addition of ribavirin may be required in certain scenarios to optimize treatment outcomes. HCV therapy in the liver transplant setting is not one-size-fits-all; thus, this review summarizes the published data and emphasizes the applicability of currently available DAA therapies in patients with decompensated cirrhosis and in liver transplant recipients.

AB - Hepatitis C virus (HCV) is a major cause of death from infectious disease and is still the leading indication for liver transplantation in the United States and other Western countries. Alloral, direct-acting antiviral (DAA) therapies have revolutionized the field, with HCV cure rates of more than 90% among treated patients. The safety and tolerability of these DAA agents have expanded the feasibility of HCV treatment even in the challenging pre- and post-liver transplant settings. However, the unique properties of DAA agents and the host profiles in these settings can limit the generalizability of HCV regimens, and prolongation of treatment duration or addition of ribavirin may be required in certain scenarios to optimize treatment outcomes. HCV therapy in the liver transplant setting is not one-size-fits-all; thus, this review summarizes the published data and emphasizes the applicability of currently available DAA therapies in patients with decompensated cirrhosis and in liver transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=85019456143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019456143&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 214

EP - 220

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 4

ER -